Table 1 Characteristics of articles included in the meta-analysis
Study ID, year | Journal | Country | Study design | Intervention | Patients, n | Median age | Male, (n%) | Median OS (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
T | C | T | C | T | C | ||||||
Mrugala 2014 [21] | Seminars In Oncology | USA | Retrospective | TTFields with compliance ≥ 75% | TTFields with compliance < 75% | 127 | 160 | 55 (18~86) | – | 13.5 | 4.0 |
Stupp 2017 [18] | JAMA | Multinati-onal | RCT | TTFields with compliance ≥ 75% | TTFields with compliance < 75% | 265 | 185 | 56 (19~83) | 316 (68%) | 22.6 | 19.1 |
Kanner 2014 [31] | Seminars In Oncology | Israel | Post hoc analysis | TTFields with compliance ≥ 75% | TTFields with compliance < 75% | 92 | 28 | 54 (24~80) | 92 (77%) | 7.7 | 4.5 |
Wong 2014 [16] | Cancer Med | USA | Post hoc analysis | TTFields with daily dexamethasone ≤ 4.1 mg | TTFields with daily dexamethasone > 4.1 mg | 14 | 106 | 54 | – | 24.8 | 6.2 |
Wong 2015 [14] | British Joutnal Of Cancer | USA | Post hoc analysis | TTFields with daily dexamethasone ≤ 4.1 mg | TTFields with daily dexamethasone > 4.1 mg | 56 | 65 | 54 (24~80) | 92 (77%) | 11.0 | 4.8 |